Our second visit of the day was to Covance. Most of us had never heard of this company before but quickly realized how large it was and the importance of it. During the presentation we learned Covance is one of the world’s largest and most comprehensive drug development services companies with more than 10,000 employees in 60 countries. Through its nonclinical, clinical and commercialization services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today. This was very intersesting because just a week earlier we had visited Beijing Asia-East Bio-Pharmaceutical Company and we were able to compare to compare the R&D, production, and distribution of these two pharmaceutical companies.
The Covance central laboratory located in Shanghai was built to further strengthen the company’s global network of full-service central laboratories and meet the growing demand for clinical trials conducted in China. The 13,000-square-foot is located in the Zhangjiang Hi-Technology Park in Pudong, Shanghai. Our speaker emphasized the importance of the Shanghai location saying that this facility is particularly strategic as China represents one of the largest growth areas in clinical development and this is exactly the purpose of our trip to China. We get to see how China is becoming a world leader in so many industries especially the pharmaceutical industry. Furthermore, during the visit, our speaker told us significant amounts about drug trials in China and a large part of Asia overall. He showed us a very detailed roadmap which gave step by step details of their drug trial process. He also gave us a brief history of the company as it pertained to the China location. The sector of the company that covers Asian countries and Australia is known as Covance Asia Pacific. They established an office in Sydney, Australia to service the Asia Pacific region in 1988, and expanded out from there. Currently, they are the longest serving international CRO office in the area. As our speaker described, Covance supports drug development from the early development state through to regional or global commercialization. As of now, they operate in three separate fields: Nonclinical Development (toxicology, research products, analytical services), Clinical Development (clinical pharmacology, clinical, central labs), and Periapproval & Market Access.
China offers many benefits for pharmaceutical and biotechnology companies conducting clinical trials, including treatment naive patients, low costs, shortened timelines for clinical trials and positive patient attitudes. Some of the most common diseases in China include cancer, cardiovascular disease, diabetes, viral disease, asthma/COPD and arthritis. After our lecture we were allowed to view the research labs that are activity perusing a cure for these diseases along with many others.
































